Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEDFIC 2 open-label extension of A4250 in children with PFIC types 1 and 2
NL-OMON54766Phase 3Recruiting
- Sponsor
- Albireo Pharma
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of odevixibat in progressive familial intrahepatic cholestasis (PFIC), progressive familial intrahepatic cholestasis type 1 (PFIC1) and progressive familial intrahepatic cholestasis type 2 (PFIC2) (2 cohorts), sponsored by Albireo Pharma. Started Dec 2018; status: recruiting.
02
Drugs
odevixibat
03
Conditions
progressive familial intrahepatic cholestasis (PFIC)progressive familial intrahepatic cholestasis type 1 (PFIC1)progressive familial intrahepatic cholestasis type 2 (PFIC2)
Beyond the preview
Go deeper on NL-OMON54766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54766.